- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05835466
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mikaela Dougherty, MS
- Phone Number: 212-241-8839
- Email: mikaela.dougherty@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Ruttenberg Treatment Center
-
Principal Investigator:
- Marina Kremyanskaya
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be ≥ 18 years of age at time of signing the ICF
- Able to voluntarily sign the ICF
- Have a pathologically confirmed diagnosis of PMF, post-ET-MF, or post-PV-MF as per the WHO diagnostic criteria with intermediate-2 or higher risk disease by DIPSS
- Have an ECOG performance status ≤ 2
- Willing to undergo a bone marrow biopsy at screening; however, a bone marrow biopsy obtained within 90 days of screening without intervening treatments and approved by the study chair may suffice.
Be refractory/resistant to or intolerant of/inappropriate for JAKi therapy as defined by at least one of the following:
- Treatment for ≥ 3 months with inadequate efficacy as demonstrated by persistent palpable splenomegaly ≥ 5cm or symptoms related to splenomegaly.
Treatment for ≥ 28 days complicated by either:
- Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months)
- NCI CTCAE grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of < 20 mg BID
- In the Investigator's judgment, are not candidates for available approved JAKi
- Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
- At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment
Have adequate organ function as demonstrated by the following:
- ALT (SGPT) and/or AST (SGOT) ≤ 3x ULN, or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to MF-related EMH);
- Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to MF-related EMH or documented Gilbert's syndrome);
- Creatinine clearance ≥ 40 mL/min ;
- Platelet count ≥ 25 x 109/L;
- Bone marrow and peripheral blood blast count < 10%;
- ANC ≥ 1000 mm3.
- Life expectancy of at least six months
- Women of childbearing potential (WCBP) and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 120 days following completion of therapy. WCBP must also have a negative serum pregnancy test at screening and Cycle 1 Day 1. Should a woman become pregnant or suspect she is pregnant while participating, she should inform her treating physician immediately.
- Ability to adhere to the study visit schedule and all protocol requirements.
Exclusion Criteria:
- Use of an investigational agent or an investigational device within 4 weeks of the first dose of study therapy
- History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
- Other invasive malignancies within the last 3 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer
Moderate or severe cardiovascular disease meeting one or both of the below criteria:
- Presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension
- Documented major ECG abnormalities (not responding to medical treatments)
- Presence of active serious infection
- Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
Participants who have undergone a hematopoietic cell transplant (HCT) within 100 days of the first dose of study therapy, participants on immunosuppressive therapy post-HCT at screening, use of calcineurin inhibitors within 4 weeks prior to first dose of study therapy, or participants with clinically significant graft-versus-host disease (GVHD)
- Note: The use of topical steroids or < 10mg oral prednisone for ongoing skin GVHD is permitted
- Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection
- Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of reparixin, including any unresolved nausea, vomiting, or diarrhea > CTCAE grade 1
- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject
- Organ transplant recipients other than bone marrow transplant
- Women who are pregnant or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reparixin
Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks).
After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
|
reparixin at 1200mg TID three times per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of reparixin treatment per IWG/ELN criteria
Time Frame: Cycle 6 (each cycle is 4 weeks) Response Assessment
|
To estimate the efficacy of reparixin treatment in DIPSS intermediate-2 or high-risk subjects with PMF, post PV-MF, or post ET-MF as assessed by IWG/ELN criteria.
The IWG/ELN criteria: CR (complete remission), PR (partial remission), Clinical improvement, Anemia response, Spleen response, Symptoms response, PD (progressive disease), SD (stable disease), Relapse, Cytogenetic remission, and Molecular remission
|
Cycle 6 (each cycle is 4 weeks) Response Assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Assessment of IWG/ELN
Time Frame: end of Cycle 6 (each cycle is 4 weeks)
|
Response by IWG/ELN criteria at the end of Cycle 6.
The IWG/ELN criteria: CR (complete remission), PR (partial remission), Clinical improvement, Anemia response, Spleen response, Symptoms response, PD (progressive disease), SD (stable disease), Relapse, Cytogenetic remission, and Molecular remission
|
end of Cycle 6 (each cycle is 4 weeks)
|
Response Assessment of IWG/ELN
Time Frame: end of Cycle 12 (each cycle is 4 weeks)
|
Response by IWG/ELN criteria at the end of Cycle 12.
The IWG/ELN criteria: CR (complete remission), PR (partial remission), Clinical improvement, Anemia response, Spleen response, Symptoms response, PD (progressive disease), SD (stable disease), Relapse, Cytogenetic remission, and Molecular remission
|
end of Cycle 12 (each cycle is 4 weeks)
|
Bone marrow fibrosis grade
Time Frame: end of Cycle 6 (each cycle is 4 weeks)
|
Bone marrow fibrosis grade at the end of Cycle 6. Bone marrow fibrosis (MF) is graded as MF-0 to MF-3, with higher number indicating more disease.
|
end of Cycle 6 (each cycle is 4 weeks)
|
Bone marrow fibrosis grade
Time Frame: end of Cycle 12 (each cycle is 4 weeks)
|
Bone marrow fibrosis grade at the end of Cycle 12. Bone marrow fibrosis (MF) is graded as MF-0 to MF-3, with higher number indicating more disease.
|
end of Cycle 12 (each cycle is 4 weeks)
|
Number of Adverse Events
Time Frame: End of study (24 weeks) plus 3 months
|
To assess the safety of reparixin as measured by the adverse event profile of CTCAE v5.0.
|
End of study (24 weeks) plus 3 months
|
Change in Spleen Volume
Time Frame: Baseline and cycle 6 (each cycle is 4 weeks)
|
Change in spleen volume by imaging after cycle 6 as compared to baseline spleen volume.
|
Baseline and cycle 6 (each cycle is 4 weeks)
|
Change in Spleen Volume
Time Frame: Baseline and cycle 12 (each cycle is 4 weeks)
|
Change in spleen volume by imaging after cycle 12 as compared to baseline spleen volume.
|
Baseline and cycle 12 (each cycle is 4 weeks)
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Marina Kremyanskaya, PhD, MD, Icahn School of Medicine at Mount Sinai
- Study Chair: Aaron Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Myeloproliferative Disorders
- Polycythemia Vera
- Polycythemia
Other Study ID Numbers
- STUDY-22-01764
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelofibrosis (PMF)
-
University of UlmActive, not recruitingPrimary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MFGermany
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)United Kingdom
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedMyelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)Germany, United States, Australia, Italy, United Kingdom
-
Kartos Therapeutics, Inc.RecruitingPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)China
-
GlaxoSmithKlineActive, not recruitingNeoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) MyelofibrosisUnited States, Canada
-
Novartis PharmaceuticalsWithdrawnPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis
-
Samus Therapeutics, Inc.TerminatedPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)United States
-
AstraZenecaUniversity of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...CompletedPrimary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia MyelofibrosisUnited States, France
Clinical Trials on reparixin
-
Dompé Farmaceutici S.p.ACompletedKidney Diseases | Ischemia-Reperfusion InjuryUnited States, France, Italy, Spain
-
Dompé Farmaceutici S.p.ATerminatedBreast CancerUnited States
-
Dompé Farmaceutici S.p.ACompletedPneumonia, ViralUnited States, Italy
-
Dompé Farmaceutici S.p.ACompletedIslet Transplantation in Diabetes Mellitus Type 1United States, Czechia, Italy, Sweden, United Kingdom
-
Dompé Farmaceutici S.p.ARecruitingAcute Respiratory Distress Syndrome, AdultUnited States, Germany, Italy
-
Dompé Farmaceutici S.p.ACompletedEarly Allograft Dysfunction | Ischemia-reperfusion Injury in Liver TransplantBelarus, Russian Federation
-
Dompé Farmaceutici S.p.AWithdrawnFatigue | Locally Advanced or Metastatic Breast CancerUnited States, Italy, Germany
-
Dompé Farmaceutici S.p.ACompletedPancreatectomy for Chronic PancreatitisUnited States, Canada
-
Dompé Farmaceutici S.p.ARecruitingSevere COVID-19 | Infectious PneumoniaUnited States, Australia, Turkey, Argentina, Germany, Austria, Italy
-
Dompé Farmaceutici S.p.ATerminated